OcuNexus Therapeutics

Oct 12, 2021

| DelveInsight The Persistent Corneal Epithelial Defects pipeline therapies expected to get launched in the forecasted period include Nexagon, ST266, RGN-259, REC-0559, and others. These are expected to create a positive shift in the Persistent Corneal Epithelial Defects market during the forecast period (2021-2030). News provided by Share this article Share this article LAS VEGAS, Oct. 12, 2021 /PRNewswire/ -- DelveInsight's Persistent Corneal Epithelial Defects (PEDs or PCEDs) Market  report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). As per DelveInsight's estimate, the total Persistent Corneal Epithelial Defects incident cases in 2020 were reported to be 241,452 in the 7MM. DelveInsight estimates that PCED affects males more as compared to females. The PCED therapy market space is monopolized by aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. The Persistent Corneal Epithelial Defects therapeutic market size appears to be dominated by the United States in 2020, worth USD 83.9 million. Key pharmaceutical and biotech companies actively engaged in the Persistent Corneal Epithelial Defects market space include OcuNexus Therapeutics, Eyevance Pharmaceuticals, and Noveome Biotherapeutics, among others. The Persistent Corneal Epithelial Defects pipeline therapies expected to launch in the forecasted period (2021-2030) include Nexagon, ST266, RGN-259, REC-0559, and others. The anticipated launch of the pipeline therapies is expected to create a positive shift in the market during the forecast period (2021-2030). Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43). The demand for novel therapies with the absence of key players led to the boosted R&D from the academic-industry partnership that led to the prompting of open innovation and prioritizing the targeting of PED. Novel therapies being investigated recently are beginning to show promise in the treatment of the nonhealing corneal epithelium. Download Persistent Corneal Epithelial Defects Market Snapshot report to understand which Persistent Corneal Epithelial Defects drug is going to capture the maximum market share @  Persistent Corneal Epithelial Defects Therapy Market Analysis and Forecast  Persistent Corneal Epithelial Defects: Disease Overview Persistent Corneal Epithelial Defects (PCED/ PED) are characterized by the failure of the rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Persistent Corneal Epithelial Defects Epidemiological Segmentation DelveInsight's Persistent Corneal Epithelial Defects Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into: Total  Persistent Corneal Epithelial Defects Incident Cases  Gender-specific PCED Incidence  Etiology-specific  Persistent Corneal Epithelial Defects Incidence  Understand how Persistent Corneal Epithelial Defects Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Persistent Corneal Epithelial Defects Epidemiology Market Report Summary The current approaches include aggressive lubrication, punctal occlusion, bandage soft contact lens, pressure patching, tetracyclines, prophylactic topical antibiotics, and steroids. Membrane grafting, autologous serum, scleral contact lenses, and others are available for relapse cases. Persistent epithelial defects of the cornea can be challenging to even the experienced ophthalmologist. Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is essential to treat the underlying causative condition, including infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. In individuals with PCEDs, there is a high risk of infection or further injury resulting in permanent vision loss due to corneal scarring, infection, neovascularization, and incomplete wound healing. The current PCED therapy market has several unmet needs in the form of a lack of adequate and curative therapies that can heal or reverse the damage to the cornea. Several pharmaceutical and biotech companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and several others are working to keep the market growth steady, showcasing an encouraging future picture. DelveInsight estimates that with an entry of pharmaceutical pharma players and the expected launch of novel therapies, the futuristic outlook of the PCED market is anticipated to be promising during the next decade. Besides, a better understanding of the condition of increased healthcare expenditure and funding from international organizations shall further add to the growth of the Persistent Corneal Epithelial Defects market share. Persistent Corneal Epithelial Defects Pipeline Therapies in focus in the report analysis Nexagon: OcuNexus Therapeutics Persistent Corneal Epithelial Defects Market Dynamics Persistent Corneal Epithelial Defects Market to grow due to rising prevalence and increased awareness about the PED and its association with other diseases and its detection. Identifying potential targets, orphan designations, market exclusivity, support from various organizations are attracting the companies to develop novel therapies, which may increase the future Persistent Corneal Epithelial Defects market growth. Nevertheless, the growth of the Persistent Corneal Epithelial Defects Market may be hindered by the poor response rate and various side effects of the available treatment option. Also, stringent regulatory procedures by regulatory authorities on medication and devices are hampering the persistent epithelial defects treatments market.